<code id='4ADAFA9F08'></code><style id='4ADAFA9F08'></style>
    • <acronym id='4ADAFA9F08'></acronym>
      <center id='4ADAFA9F08'><center id='4ADAFA9F08'><tfoot id='4ADAFA9F08'></tfoot></center><abbr id='4ADAFA9F08'><dir id='4ADAFA9F08'><tfoot id='4ADAFA9F08'></tfoot><noframes id='4ADAFA9F08'>

    • <optgroup id='4ADAFA9F08'><strike id='4ADAFA9F08'><sup id='4ADAFA9F08'></sup></strike><code id='4ADAFA9F08'></code></optgroup>
        1. <b id='4ADAFA9F08'><label id='4ADAFA9F08'><select id='4ADAFA9F08'><dt id='4ADAFA9F08'><span id='4ADAFA9F08'></span></dt></select></label></b><u id='4ADAFA9F08'></u>
          <i id='4ADAFA9F08'><strike id='4ADAFA9F08'><tt id='4ADAFA9F08'><pre id='4ADAFA9F08'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:68142
          Doctor Monica Bertagnolli, a white woman with short hair and bangs, sits at a hearing behind her name tag — coverage from STAT
          National Institutes of Health Director Monica Bertagnolli testifies during her Senate HELP Committee confirmation hearing on Oct. 18 in Washington. Kevin Dietsch/Getty Images

          WASHINGTON — The new National Institutes of Health director, Monica Bertagnolli, said it’s a “failure” that enrollment in government-funded clinical trials has lagged behind those funded by the pharmaceutical industry.

          “If you just look at the number of patients who go on government-funded trials, it’s been completely flat over the last decade,” she said at a meeting of the advocacy group Friends of Cancer Research. “If you go and look at the number of people who go on pharma-sponsored trials, it’s just this commitment and this increase.”

          advertisement

          A Johns Hopkins University study published in 2015 showed that the pharmaceutical industry funds six times more clinical trials than the government. Industry-sponsored trials increased 43% from 2006 to 2014, while newly registered NIH-funded trials decreased 24% over the same period.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira
          AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

          AbbvieCEORichardGonzalezwillstepdowninJuly.JacquelynMartin/APAbbVieannouncedTuesdaythatCEORichardGon

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Can medical device makers keep up in the race to treat obesity?

          KatyLemayforSTATThemakersofminimallyinvasivesurgicaldevicesseemedpoisedtocaptureawideswathoftheobesi